摘要
目的探讨莫西沙星联合HRZE方案治疗初治肺结核患者的临床疗效及安全性。方法选取2016年2月—2017年2月我院收治的初治肺结核患者98例为研究对象,采用回顾性分析法分析所有患者的临床资料,按照资料中其治疗方法的不同将98例患者分为对照组和观察组,每组49例。对照组给予HRZE常规抗结核方案治疗,观察组在对照组的基础上加用莫西沙星治疗,观察并比较二组患者的痰菌阴转情况、肺部病灶及空洞变化情况及不良反应情况。结果 (1)二组患者化疗2个月末、6个月末时痰转阴率比较差异具有统计学意义(P<0.05)。(2)影像学检查结果显示观察组病灶吸收有效率(91.84%)明显高于对照组(73.47%)(P<0.05)。观察组肺空洞变化有效率(77.55%)较对照组(69.39%)高,但比较差异无统计学意义(P>0.05)。(3)二组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论莫西沙星联合HRZE方案治疗初治肺结核患者可以提高痰转阴率,提高病灶吸收有效率,且不增加不良反应的发生率,安全性可靠,值得临床推广应用。
Objective To investigate clinical effect and safety of moxifloxacin combined with HRZE regimen on treatment-naive pulmonary tuberculosis.Methods The clinical data of 98 newly diagnosed tuberculosis patients admitted to author＇s hospital from February 2016 to February 2017 were retrospectively analyzed.And 98 patients were divided into control group and observation group,each with 49 cases.The control group was given HRZE conventional anti-TB regimen,and based on this,patients in the observation group was treated with moxifloxacin.The negative conversion rate of sputum bacteria,pulmonary lesions absorption efficiency,empty hole conversion and adverse reactions in the two groups were observed and compared.ResultsThe negative conversion rate of sputum bacteria showed a significant difference between the two groups at the end of 2 months and at the end of 6 months of chemotherapy（P〈0.05）.The results of imaging examination showed that the absorption efficiency in the observation group was significantly higher than that in the control group（91.84% vs 73.47%,P〈0.05）.The effective rate of empty hole conversion in observation group was higher than that of control group（77.55% vs 69.39%）,with no statistical difference（P〉0.05）.The incidence of adverse reactions between the two groups held no significant difference（P〉0.05）.Conclusion Moxifloxacin combined with HRZE regimen is a safe and reliable way to improve the negative conversion rate of sputum bacteria and pulmonary lesions absorption efficiency on treatment-naive pulmonary tuberculosis without increasing the adverse reactions,which is worthy of clinical applications.
作者
刘长利
南琴
石海平
Liu Changli;Nan Qin;Shi Haiping(The First Branch Department of Medicine, Tuberculosis Control of Shaanxi Province, Xi ＇an 710100, China)
出处
《中国煤炭工业医学杂志》
2018年第1期20-24,共5页
Chinese Journal of Coal Industry Medicine
基金
陕西省卫生科研基金项目(编号:2012D65)
关键词
肺结核
莫西沙星
HRZE方案
Pulmonary tuberculosis
Moxifloxacin
HRZE regimen
Clinical effect
Safety
